DK3858375T3 - Behandling af koagulationssygdom ved administration af rekombinant vwf - Google Patents

Behandling af koagulationssygdom ved administration af rekombinant vwf Download PDF

Info

Publication number
DK3858375T3
DK3858375T3 DK20216368.9T DK20216368T DK3858375T3 DK 3858375 T3 DK3858375 T3 DK 3858375T3 DK 20216368 T DK20216368 T DK 20216368T DK 3858375 T3 DK3858375 T3 DK 3858375T3
Authority
DK
Denmark
Prior art keywords
administration
treatment
recombinant vwf
coagulation disease
coagulation
Prior art date
Application number
DK20216368.9T
Other languages
Danish (da)
English (en)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3858375T3 publication Critical patent/DK3858375T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20216368.9T 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf DK3858375T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15
EP18173179.5A EP3412305B1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Publications (1)

Publication Number Publication Date
DK3858375T3 true DK3858375T3 (da) 2024-04-15

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20216368.9T DK3858375T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf
DK12728919.7T DK2717905T3 (en) 2011-06-10 2012-06-11 TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
DK18173179.5T DK3412305T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK12728919.7T DK2717905T3 (en) 2011-06-10 2012-06-11 TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
DK18173179.5T DK3412305T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR101969515B1 (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT3858375T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10202002591QA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
DK3648788T3 (da) * 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) * 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
SG11202009213TA (en) * 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体c1qの複合体に関連する治療法
BR112022015326A2 (pt) * 2020-02-04 2022-10-11 Takeda Pharmaceuticals Co Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
AU2008261261B2 (en) * 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2865760T3 (en) * 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011017414A2 (en) * 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Also Published As

Publication number Publication date
US20120316116A1 (en) 2012-12-13
EP2717905A1 (en) 2014-04-16
AU2022201518A1 (en) 2022-03-24
SG10202002591QA (en) 2020-05-28
KR20140039285A (ko) 2014-04-01
RU2017102679A (ru) 2018-12-19
JP2019048892A (ja) 2019-03-28
US9272021B2 (en) 2016-03-01
EP3412305B1 (en) 2021-01-06
AR086904A1 (es) 2014-01-29
JP6347468B2 (ja) 2018-06-27
US20160184403A1 (en) 2016-06-30
CN108210889A (zh) 2018-06-29
RU2017102679A3 (enExample) 2018-12-19
KR20190041032A (ko) 2019-04-19
DK2717905T3 (en) 2018-07-02
CN107412743A (zh) 2017-12-01
CA2838845A1 (en) 2012-12-13
PL3858375T3 (pl) 2024-05-20
KR102319868B1 (ko) 2021-11-01
WO2012171031A1 (en) 2012-12-13
CA2838845C (en) 2019-08-06
HK1257436A1 (zh) 2019-10-18
MX350582B (es) 2017-09-11
BR112013031795A2 (pt) 2016-12-20
RU2019103386A (ru) 2020-08-07
JP2014516088A (ja) 2014-07-07
PL2717905T3 (pl) 2018-10-31
PL3412305T3 (pl) 2021-05-31
SI2717905T1 (sl) 2018-09-28
CN103732244A (zh) 2014-04-16
MX2013014543A (es) 2014-06-11
KR20200091476A (ko) 2020-07-30
ES2860450T3 (es) 2021-10-05
KR101969515B1 (ko) 2019-04-16
RU2014100107A (ru) 2015-07-20
PT2717905T (pt) 2018-07-02
AU2020200026A1 (en) 2020-01-30
DK3412305T3 (da) 2021-03-01
JP6527114B2 (ja) 2019-06-05
RU2628537C2 (ru) 2017-08-18
FI3858375T3 (fi) 2024-04-17
PT3858375T (pt) 2024-04-18
MX2020000083A (es) 2020-08-06
ES2976169T3 (es) 2024-07-24
HRP20180962T1 (hr) 2018-10-19
AU2017206235A1 (en) 2017-08-03
EP3858375A1 (en) 2021-08-04
CN107412743B (zh) 2021-07-02
JP2017019788A (ja) 2017-01-26
EP3412305A1 (en) 2018-12-12
AU2017206235B2 (en) 2019-10-17
RU2680402C2 (ru) 2019-02-21
ES2682249T3 (es) 2018-09-19
US20250387455A1 (en) 2025-12-25
AU2012267458A1 (en) 2014-01-09
HUE039317T2 (hu) 2018-12-28
PT3412305T (pt) 2021-01-29
LT2717905T (lt) 2018-10-10
AU2016202299B2 (en) 2017-07-20
EP2717905B1 (en) 2018-05-23
AU2016202299A1 (en) 2016-05-05
NZ618790A (en) 2015-07-31
RU2019103386A3 (enExample) 2022-01-24
AU2022201518B2 (en) 2025-07-03
EP3858375B1 (en) 2024-03-20
SG10201604684WA (en) 2016-07-28
TR201808823T4 (tr) 2018-07-23

Similar Documents

Publication Publication Date Title
DK3412305T3 (da) Behandling af koagulationssygdom ved administration af rekombinant vwf
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CO6930321A2 (es) Curación de tejidos
DK2931891T3 (da) Rna-styret modificering af menneskelige genomer
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK2717941T3 (da) Behandling af cancer
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
DK2844279T3 (da) Doseringsprogrammer til behandling af pompes sygdom
DK3011936T3 (da) Vævsmanipulerede konstrukter
DK2785349T3 (da) Kombinationsbehandling af cancer
DK2701697T3 (da) Oxidative nethindesygdomme
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
DK2773379T3 (da) Subkutan indgivelse af polymerkonjugater af terapeutiske midler
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK3603704T3 (da) Indgivelse af medikament
EP2734841A4 (en) PHOTONIC BLOOD GROUP DETERMINATION
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
IL231121A0 (en) Treatment of degenerative joint disease
LT2768859T (lt) Il17c antagonistai, skirti uždegiminių ligų gydymui
EP2750709A4 (en) TREATMENT OF KACHEXIE
DK2673363T3 (da) Behandling af angiogenesesygdomme
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
PT2493147E (pt) Agulha flash de sangue